Jueves y Viernes de Oferta Flash: Hasta 70% dcto  Ver más

Enviar a
Bogota, Cundinamarca
0
  • argentina
  • chile
  • colombia
  • españa
  • méxico
  • perú
  • estados unidos
  • internacional

Selecciona tu país

América

Europa

Resto del mundo

portada Efficacy and Comparative Effectiveness of Off-Label Use of Atypical Antipsychotics: Comparative Effectiveness Review Number 6 (en Inglés)
Formato
Libro Físico
Editorial
Idioma
Inglés
N° páginas
378
Encuadernación
Tapa Blanda
Dimensiones
28x21.6x2 cm
Peso
0.88 kg.
ISBN13
9781490528137

Efficacy and Comparative Effectiveness of Off-Label Use of Atypical Antipsychotics: Comparative Effectiveness Review Number 6 (en Inglés)

U. S. Department of Heal Human Services (Autor) · Agency for Healthcare Resea And Quality (Autor) · Createspace · Tapa Blanda

Efficacy and Comparative Effectiveness of Off-Label Use of Atypical Antipsychotics: Comparative Effectiveness Review Number 6 (en Inglés) - And Quality, Agency for Healthcare Resea ; Human Services, U. S. Department of Heal

Libro Nuevo Importado
Envío: 18 a 24 días háb.
$ 221.719$ 133.031
-40%
Costos de importación incluídos en el precio ✅
Libro Nuevo

Quedan 100 unidades

$ 133.031
¡Envío Gratis!  Llega entre el 18 Dic y el 30 Dic a Bogota, Cundinamarca. Seleccionar ubicación

Reseña del libro "Efficacy and Comparative Effectiveness of Off-Label Use of Atypical Antipsychotics: Comparative Effectiveness Review Number 6 (en Inglés)"

Antipsychotic medications, widely used for the treatment of schizophrenia and other psychotic disorders, are commonly divided into two classes, reflecting two waves of historical development. The conventional antipsychotics--also called typical antipsychotics, conventional neuroleptics, or dopamine antagonists--first appeared in the 1950s and continued to evolve over subsequent decades, starting with chlorpromazine (Thorazine), and were the first successful pharmacologic treatment for primary psychotic disorders, such as schizophrenia. While they provide treatment for psychotic symptoms - for example reducing the intensity and frequency of auditory hallucinations and delusional beliefs - they also commonly produce movement abnormalities, both acutely and during chronic treatment, arising from the drugs' effects on the neurotransmitter dopamine. These side effects often require additional medications, and in some cases, necessitate antipsychotic dose reduction or discontinuation. Such motor system problems spurred the development of the second generation of antipsychotics, which have come to be known as the "atypical antipsychotics." Currently, the U.S. Food and Drug Administration (FDA)-approved atypical antipsychotics are aripiprazole, clozapine, olanzapine, quetiapine, risperidone, and ziprasidone. Off-label use of the atypical antipsychotics has been reported for the following conditions: dementia and severe geriatric agitation, depression, obsessive-compulsive disorder, posttraumatic stress disorder, and personality disorders. The purpose of this Evidence Report is to review the evidence supporting such off-label uses of these agents. We were also asked to study the use of the atypical antipsychotics for the management of Tourette's Syndrome and autism in children. The medications considered in this report are those listed above; however, we have excluded clozapine, which has been associated with a potentially fatal disorder of bone-marrow suppression and requires frequent blood tests for safety monitoring. Because of these restrictions, it is rarely used except for schizophrenia that has proven refractive to other treatment. The Key Questions were: Key Question 1. What are the leading off-label uses of atypical antipsychotics in the literature? Key Question 2. What does the evidence show regarding the effectiveness of atypical antipsychotics for off-label indications, such as depression? How do atypical antipsychotic medications compare with other drugs for treating off-label indications? Key Question 3. What subset of the population would potentially benefit from off-label uses? Key Question 4. What are the potential adverse effects and/or complications involved with off-label prescribing of atypical antipsychotics? Key Question 5. What are the appropriate dose and time limit for off-label indications?

Opiniones del libro

Preguntas frecuentes sobre el libro

Todos los libros de nuestro catálogo son Originales.
El libro está escrito en Inglés.
La encuadernación de esta edición es Tapa Blanda.

Preguntas y respuestas sobre el libro

¿Tienes una pregunta sobre el libro? Inicia sesión para poder agregar tu propia pregunta.

Opiniones sobre Buscalibre

Ver más opiniones de clientes